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Abstract
Multiple sclerosis (MS) is an immune-mediated disease in which inflamma-
tory lesions form in the brain. In many active MS lesions, the blood-brain bar-
rier (BBB) is disrupted and blood flows into white matter; this disruption may
be related to morbidity and disability. Dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) allows quantitative study of blood flow and
permeability dynamics throughout the brain. This technique involves a subject
being imaged sequentially during a study visit as an intravenously administered
contrast agent flows into the brain. In regions where flow is abnormal, such
as white matter lesions, this allows the quantification of the BBB damage. A
DCE-MRI sequence acquired at a single visit is a spatiotemporal process that
consists of MR intensity observed at millions of voxels (space) using multiple
MRI scans over a period of 15-160 minutes in the scanner (time). In our study,
we observe 15 patients who undergo DCE-MRI periodically throughout a year.
The longitudinal nature of the study arises from the multiple visits where MRI
is conducted for each subject. In this paper, we are interested in designing
and studying spatiotemporal parameters of interest that cannot be obtained
by visual inspection. Examples of such parameters are the rate and maximum
intensity observed in regions of interest. We use functional principal compo-
nent analysis (FPCA) and semiparametric techniques for this quantification
of BBB disruption at each visit. The longitudinal evolution of maps of such
parameters provides a useful clinical tool for quantification and visualization
of BBB abnormalities. Using these techniques we find evidence of subtle en-
hancement in a chronic white matter lesion, which is previously undocumented
using DCE-MRI in MS.
Keywords: functional principal components analysis, dynamic contrast-enhanced
magnetic resonance imaging, imaging, information criteria, longitudinal data
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1 Introduction
Multiple sclerosis (MS) is an immune-mediated disease in which inflammatory lesions
form in the brain. In many active MS lesions, the blood-brain barrier (BBB) is
disrupted and blood flows into the white matter. This disruption is known to be
related to morbidity and disability (Raine et al., 1997). The number of lesions in which
there is clear evidence of BBB breakdown is a common outcome in clinical trials for
MS treatments, and is used as a measure of disease activity in the clinical management
of patients (Polman et al., 2011). BBB breakdown is assessed in clinical practice and
research through the use of contrast-enhanced magnetic resonance imaging (MRI).
In particular, intravenous contrast agents with specific magnetic properties are given
to patients and the pre- and post-injection images are qualitatively compared to find
areas of abnormal blood flow.
In this paper, we consider a natural history study conducted at the National
Institute of Neurological Diseases and Stroke. The brains of 15 subjects were im-
aged several times sequentially during each study visit. This technique, known as
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), allows quanti-
tative study of blood flow throughout the brain. DCE-MRI involves first acquiring
one or more images before any contrast agent is given. An intravenous contrast agent,
in our case a gadolinium chelate, is then administered. As the contrast agent has spe-
cific magnetic properties, areas in which it is present are hyperintense on T1-weighted
MRI. Therefore, lesions in which the contrast agent is abnormally present are said to
enhance. By acquiring these images sequentially over a period of minutes to hours
after the injection, we can study the integrity of the BBB in the brain.
[Figure 1 here]
The observed data for one subject in one slice of brain at three visits (early
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March, late March and May of the same year) are shown in Figure 1. The axial
slice on the left is a baseline image taken before any contrast agent is administered.
In the right section of the figure, a particular lesion is shown in more detail; the
smaller images show this region magnified. Each row corresponds to data acquired
during a single study visit with time in the scanner elapsing from left to right and
each column corresponding to the within-visit time at which the image was taken. A
quick inspection of the visit from early March shows that there is very little change
between scans after gadolinium injection, indicating that there is no recognizable BBB
disruption. Although there is also no obvious change over time in late March either,
the average intensity is much brighter at this visit. This does not reflect a difference
in the patient’s brain between the two visits, but rather random variation attributable
to the scanner. On the scan from May, there is a clear elliptical brightening in the
region as time proceeds (moving left to right) and the contrast agent leaks in. For
clarity, we show the region of interest (ROI) using a green contour. Our goal in
this paper is to quantify these spatiotemporal processes longitudinally. We proceed
by characterizing parameters which are difficult to quantify visually such as: 1) the
rate of enhancement, which is affected by a combination of blood flow and BBB
permeability; and 2) maximum enhancement intensity, which is indicative of the
level of accumulation of blood in these areas and therefore reflects a combination of
permeability to and clearance of the contrast agent.
Figure 1 shows a small subset of the data from one subject at only three visits.
In this paper we consider 92 DCE-MRI scans of 15 subjects taken over the course
of 12 months with a median between-visit time of 30 days. Patients gave informed
consent and the protocol was approved by an institutional review board. At each
visit, between 11 and 67 T1-weighted MRIs were acquired over a time period ranging
from 16 to 155 minutes; several MRIs were taken prior to gadolinium administration,
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and then between 8 and 64 MRIs were taken over 10 to 146 minutes in order to assess
the leakage of blood into the lesions. These data are very large, ranging from 80
million to 482 million (time series by space) observed intensities for each visit and
each subject. This makes computation using modern computing facilities challenging.
In this paper, our goal is to model longitudinal trends in enhancement both within
and across scan sessions. These spatiotemporal features can be dramatic or subtle,
and their qualitative study has been of interest concerning the etiology of MS lesions
(Gaita´n et al., 2011). In the next section, we review standard approaches for the
analysis of DCE-MRI data. We then consider refinements and alternatives to the
current techniques that address our scientific goal, and we introduce methodology for
longitudinal quantitative analysis in a statistically principled framework. We conclude
with a discussion.
2 Existing Methods
The DCE-MRI data are preprocessed using Medical Image Processing Analysis and
Visualization (MIPAV) (http://mipav.cit.nih.gov) and the Java Image Science Toolkit
(JIST) (Lucas et al., 2010). All images are registered and voxels outside of the brain
are removed using a skull-stripping procedure (Carass et al., 2007). The data are
interpolated to a grid of voxels measuring 1mm x 1mm x 1mm from the acquired
resolution of 2mm x 2mm x 2mm. The Lesion-TOADS automatic segmentation
algorithm (Shiee et al., 2010) is applied to the data from each visit, which identifies
voxels as normal-appearing white matter, white matter lesions, or other tissue types
(including gray matter and cerebrospinal fluid.
The first step in an analysis of DCE-MRI data is to normalize the images. We pro-
ceed as in Shinohara et al. (2011) by subtracting the mean and dividing by the stan-
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dard deviation of normal-appearing white matter intensities from the pre-injection
data. This normalization procedure is fast and emphasizes departures from healthy
white matter in the brain. It allows comparison of enhancement features across scans
and across subjects. In particular, in Figure 1, the images from the early March
visit appeared darker than those from the late March visit; our normalization scheme
addresses this issues. After normalization, the units are interpretable as standard
deviations of the natural variation of the intensity in healthy white matter.
The intensity measured at each voxel within each study visit may be considered as
a time series, hence the subject/visit specific data can be viewed as a spatiotemporal
process. There are two standard approaches which have been described in the liter-
ature: the first involves parametric techniques using pharmacokinetic models. These
models are susceptible to instability and misspecification when applied to whole brain
data, dramatically restricting their utility for the study of populations. An alternative
approach uses functional principal component analysis (FPCA) in the entire brain to
quantify enhancement. These methods are described below and their advantages and
limitations are compared.
2.1 Pharmacokinetic Modeling
Traditionally, DCE-MRI data are analyzed using standard fully parametric pharma-
cokinetic modeling techniques (Davidian and Giltinan, 1995; Tofts et al., 1999) in
isolated regions of interest. Between these regions, the temporal behavior of intensi-
ties differs drastically and thus different parametric models must be fit in the different
areas of the brain. This requires careful (often manual) segmentation of the brain
into anatomical regions which is slow and costly in larger studies, and incorrectly
fitting models outside of their appropriate regions leads to dramatic instability. In
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fact, fitting standard pharmacokinetic models in all voxels from the brain leads to
failure in a majority of the voxels. For our attempts, 70-90% of the voxels can either
not be fit or have fitted parameters that are not interpretable. This occurs for several
reasons: 1) the time series in various areas of the brain are so different that no simple
parametric model fits all of their behaviors well; 2) fully parametric pharmacokinetic
models require numerical optimization procedures that are sensitive to starting val-
ues and require careful restriction of the parameter space; and 3) compartmental
models may be overly simplistic for the complex spatial-temporal kinetic processes in
neuro-vascular contrast agents.
To clarify these problems, we focus on the three most prominent behaviors ob-
served in normal-appearing white matter, blood vessels, and enhancing lesion voxels.
We suggest parametric forms that approximate these shapes well. For voxels that
show no changes after the contrast injection, we fit a constant model f1(t) = c. The
blood vessel behavior is fit as f2(t) = ψ1+ψ2φ(t), where ψ1 and ψ2 > 0 are constants,
and φ(t) is the second whole-brain principal component (described in more detail
below, and shown in Figure 3). Although this may be parametrized in an analytical
form, the precise gadolinium concentration in these regions is not of interest in this
work, and the general shape of the time series is well-approximated using this princi-
pal component. For the enhancing white-matter voxels, we fit the parameters y0, a, b,
and α in the model:
f3(t) =


y0 if t ≤ α
a
{
1
1+exp[−b(t−α)]
− 1
2
}
+ y0 if t > α
(1)
Examples of the fitted values from these parametric models are shown in Figure
2. These plots show how each model fits three observed time series from voxels from
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each (possibly incorrect) anatomical location in our data (indicated by the color of
the points). It is clear that the parametric models perform well in their appropriate
regions (shown on the diagonal), but they fail when applied improperly (in the plots
off of the diagonal where the colors of the line and points do not match). The
situation shown in Figure 2 is a highly idealized scenario where we manually extracted
3 voxels out of the roughly 1.6 million in the brain to emphasize specific expected
behaviors. A serious difficulty in brain imaging research is that there is no or only
limited information about what the individual local behavior is and what model would
be appropriate at specific voxels.
Another major limitation is that most voxels do not change appreciably after
the contrast agent is administered; indeed, all healthy white matter behaves in this
manner. This is problematic in pharmacokinetic models, including (1), as non-
enhancement is on a boundary of the parameter space. For example, model (1)
has an identifiability problem when fitting a constant, as if either a = 0 or b = ∞
the other parameter vanishes. This causes instability in cases where there is no en-
hancement or enhancement is subtle. Such voxels vastly outnumber the other types of
voxels, as large areas of the brain are neither blood vessels nor visibly enhancing. In
these situations, fitting model (1) leads to very large values of b or very small values
of a that are ultimately uninterpretable. Thus, in a context where one is interested
in enhancement without knowing which voxels enhance, the appeal of the method is
drastically reduced. Finally, fitting the simple model (1) throughout a single subject’s
brain using a modern statistical package on a personal computer takes days, making
the analysis of populations of DCE-MRI data wasteful and impractical (calculations
performed in R, R Development Core Team (2011), on an Apple Mac Pro with two
3.2Ghz Quad-Core Intel Xeon processors and 20Gb of RAM).
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[Figure 2 here]
2.2 FPCA-based Methods
To avoid these issues, Shinohara et al. (2011) suggestde an FPCA-based approach and
demonstrated their methods on 10 subjects suffering from MS. Shinohara et al. (2011)
interpreted the principal components (PCs) and quantified enhancement patterns at
the voxel-level using the first few PC scores.
To apply this method, we first interpolate our normalized data linearly to a com-
mon equally-spaced time grid t1, . . . , t100 from 20 minutes before injection to 72 min-
utes post-injection. To estimate the directions of maximal variation in the population,
we apply FPCA to the intensity time series from all brain voxels.
[Figure 3 here]
In our population of 92 scans, we use the FPCA approach on all voxels in the brain,
and the first 4 PCs, which explain over 99.5% of the variance, are shown in the top row
of Figure 3. Notably, the principal components are contextually very interpretable.
The first PC is a vertical shift, which explains differences between voxels that are
only minimally affected by the presence of the contrast agent. The second PC shows
an early peak followed by an approximately exponential decay, exactly the behavior
observed in blood vessels. The third and fourth PCs explain the most prominent
features of enhancement. In the bottom row of Figure 3, we show maps of the scores
in the axial slice shown in Figure 1 from the May visit for illustration. Clearly, the
second, third, and fourth PCs have higher scores in the enhancing lesion of interest.
Our PCs are very similar to those from Shinohara et al. (2011).
To classify enhancement versus non-enhancement in a particular voxel, Shinohara
et al. (2011) suggested hypothesis testing in the space of PC scores from white-matter
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voxels. To conduct this testing, they suggest robustly fitting a multivariate normal
density to the central cluster of non-enhancing white-matter voxels.
For the quantification of enhancement that is found in each of these lesions, Shino-
hara et al. (2011) considered modeling the relationship between the third and fourth
PC scores. Although we are interested in enhancement behaviors in ROIs, there are
many other (healthy) behaviors that are observed in blood vessels and outside the
brain. These behaviors dominate the whole-brain FPCA analysis as they may be
more apparent and may occur in more voxels. Thus, to quantify enhancement in
white matter lesions more carefully, we require methods tuned for these regions.
3 Visit-Specific Techniques
In this section, we consider methods that are refinements of the existing parametric
and nonparametric techniques described in the last section. In particular, we suggest
methods that are designed to quantify enhancement behaviors within enhancing ROIs
as identified using the whole-brain analysis. The first method we introduce is based on
FPCA, and then we consider a semiparametric alternative. We apply both methods
to all of our data from the 92 scans, and we compare the results.
3.1 Visit-level Analysis: Within-ROI FPCA Analysis
To examine the behavior of voxels in subject-level ROIs, we consider a second stage
of FPCA analysis restricted to voxels in these regions. In the original analysis, some
more subtle features of enhancement that occurred just following the contrast injec-
tion were missed due to the relatively coarse time grid. For voxels in our ROI, we
interpolate on a finer time grid s1, . . . , s1000 that allows us to examine these features;
such a fine time grid is computationally more difficult for the whole-brain analysis.
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[Figure 4 here]
We apply FPCA to the time series data from all voxels in the enhancing ROIs
identified using the whole-brain analysis in all of the sequences. The first three ROI-
level PCs (ROIPCs) which explain 99% of the variation in these voxels are shown
in Figure 4. These are quite different from those shown in Figure 3, which is to be
expected as many of the various time series behaviors observed in other areas of the
brain, such as blood vessels, are unlikely to be in the ROIs. The fourth and later PCs
are noisy and explain only 1% of the variation in the ROIs. Above each ROIPC, we
show the corresponding score map of the ROI shown in Figure 1 (the tilted ellipsoid
in the top of each plot).
Similarly to the whole-brain analysis, the first ROIPC is roughly a vertical shift,
which explains variation between voxels that changes little over time; in particular, it
explains baseline differences between the voxels in the ROIs. The second ROIPC is a
typical enhancement shape, and the third component helps to explain earlier versus
later enhancements. That is, a voxel that enhances faster has a high second ROIPC
score and a high third ROIPC score, whereas a slower enhancing voxel has a high
second ROIPC loading but a lower third ROIPC score. The lesion shown in the top
row of Figure 4 falls into the latter category. The simultaneous interpretation of these
scores is more difficult, and thus we consider semiparametric modeling techniques in
the next section that are easier to interpret.
3.2 Visit-level Analysis: Parametric model selection
Although fully parametric modeling techniques are not directly applicable to the
whole-brain DCE-MRI data, we suggest a semiparametric approach that addresses
this issue. We again restrict our interest to the enhancing ROIs found using whole-
11
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brain FPCA techniques. Voxels within the ROIs tend to be either enhancing or
constant, but a few blood vessel voxels may be included due to errors in segmentation
or other reasons.
Within these ROIs at each visit, we perform a fit-based selection at each voxel
among the three parametric models described in Section 2. To avoid identifiability
issues in the case of non-enhancement, we restrict ψ2 > 5 for the blood vessel model
and a > 0.1, α ≥ 0, and b ≤ 5 for the enhancing lesion model (1). These values are
chosen empirically. As these models are not nested and have different numbers of
parameters, we introduce the effective parsimony information criterion (EPIC):
EPIC(v) = log[L(t; v, θˆ(t, v))]− γ · k, (2)
where L is the likelihood, θˆ(t, v) is a general label for model parameter estimates for
all parametric models, k is the number of parameters in that model, and γ > 0 is a
penalty on the number of parameters.
Note that γ = 2 corresponds to the well-known Akaike Information Criterion
(AIC), which tends to favor more complex models (Akaike, 1974), and γ = log(n),
where n is the the number of time points, corresponds to the Bayesian Information
criterion (Schwarz, 1978). Instead, we choose γ = 4, roughly corresponding to the
95th percentile of the χ21 distribution. This choice of γ makes the maximization of
EPIC correspond to a likelihood ratio test at level 0.05 in the case of testing for one
extra parameter between two nested models. We call this model semiparametric as
it involves the nonparametric whole-brain FPCA for the identification of enhancing
ROIs and the parametric modeling using EPIC.
To compare the results from the EPIC-based and the two-stage FPCA approaches,
we consider two functionals of interest from the time series: the maximum intensity
12
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over the period of observation and the maximum derivative of the time series. The
maximum derivative is known (from inspection of the time series and from prior
scientific knowledge) to occur just after the contrast injection and is a measure of
enhancement “rate.” This is thought to be a combined measure of blood flow and
permeability of the BBB, which is of scientific and clinical interest as an indicator of
disease activity.
[Figure 5 here]
Using the EPIC approach, we estimate these quantities directly in enhancing
voxels from the fitted model (1), and we show the results for the ROI from Figure 1
at the May visit in the right column of Figure 5a. Although our methodology does not
allow us to give parameter estimates from model (1) in early March (as EPIC has not
chosen model (1) at this time point), the lesion is not enhancing in early March and
thus we are less interested in enhancement rate or magnitude at this earlier visit. To
estimate these quantities nonparametrically using the FPCA results, we first smooth
the data by projection onto the span of the first ten ROIPCs and then calculate
the maximum empirical derivative and the observed maximum of the projected data.
These estimates are shown in the left column of the Figure 5a.
The maximum intensity estimates from the two-stage FPCA and EPIC methods
are nearly identical at this visit in this ROI; see the two top panels labeled maximum
intensity in Figure 5. Thus, the two methods agree concerning the extent of enhance-
ment in this lesion. There is a clear discrepancy between the results for the maximum
derivative, however. The FPCA-based map shows a roughly symmetric ellipsoid in
the ROI whose center enhances at a greater rate. This differs from the EPIC map,
which shows the top right hand corner to have the highest enhancement rate.
To examine this discrepancy more carefully, we show the observed time series for
13
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two subregions in Figure 5b. The left column of plots shows a region where the ROIPC
analysis indicates the maximum rate of enhancement, whereas the right column shows
voxels which EPIC identifies as the fastest enhancing. At the bottom of these plots,
short vertical lines indicate the times at which the intensities were measured. The
subregion shown on the right indicates similar fits between the FPCA- (shown in the
middle row) and EPIC-based methods (shown in the bottom row).
There is a striking difference between the two model fits for the time series in the
left column, however. That is, those with higher rate according to the FPCA analysis
seem to have a sudden increase in intensity after injection, followed by a gradual
increase over a half hour. After carefully examining the scanning times, however, we
notice that this continual increase is not observed; these are interpolations. These
linear interpolations affect the FPCA analysis, but not the semiparametric model fits.
The parametric fits (shown in the bottom row), on the other hand, rely on model 1
for interpolation.
The discrepancy in estimated rates between the two models in these subregions
arises from the higher observed intensities later in the sequence, around 30 minutes
post-injection. The time series shown on the left have a much higher final intensity.
As no data were observed between 5 and 25 minutes and the observed intensity in
the first few minutes only rises up to about 3 normalized units, the FPCA fits the
observed data by linear interpolation upwards. The parametric model instead fits
the early observations as part of the initial rise and suggests that the intensities
in these voxels level off after about 5 minutes. This stretches the curve to the right,
effectively decreasing the derivative. These discrepancies suggest that either the linear
interpolation could be incorrect, or model 1 may not be sufficiently flexible. In this
ROI observed at this visit, however, we have no data with which to reconcile these
possibilities.
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This highlights a crucial point: when data are observed sparsely, as is often the
case with DCE-MRI, modeling plays a pivotal role. The analysis of data using both a
nonparametric FPCA-based method and fully or semiparametric modeling techniques
allows us to explore these assumptions and their consequences on our results. If the
nonparametric and parametric results are similar, then we are encouraged to trust
the parametric model fits. On the other hand, if they are at odds, more careful
examination of the observed data is required.
4 Longitudinal Modeling
To quantify longitudinal changes, we define subject-level ROIs by taking the union
of spatially overlapping scan-level ROIs. These subject-level ROIs allow comparisons
to be made in the voxel-specific and ROI-level properties across visit dates. By
definition, each voxel in these ROIs is known to have been enhancing at one of the
study visits from the whole-brain FPCA described in Section 2.2. ROIs with less than
30 voxels are ignored as their diameter is smaller than two acquired voxels, making
them too small to study longitudinally. Table 1 shows the number of ROIs larger
than 30 voxels detected in each subject, as well as several baseline characteristics.
[Table 1 here]
As our interest is to quantify spatiotemporal trends longitudinally, we consider
partitioning of the ROI into spatial subregions. We chose to use the minimum dis-
tance from a boundary for this; we avoided defining a centroid of the ROI as many
MS lesions have irregular shapes due to anatomical restrictions and boundaries are
easier to define and estimate (Shinohara et al., 2011). In this section, we proceed by
quantifying enhancement at each visit using both the two-stage FPCA and the semi-
15
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parametric EPIC-based methods, and we use these results to model the evolution of
enhancement in lesions over time. For convenience, we restrict our illustrations to the
subject-level ROI (indicated by a green contour) from the lesion depicted in Figure
1.
4.1 Longitudinal Two-Stage FPCA Analysis
To track and model longitudinal changes in enhancement between visits, we first
consider the results from the two-stage FPCA across calendar time. We calculate
the scores on the ROIPCs for each voxel in the ROI at each study visit. We may
consider the longitudinal trends in the scores themselves, but these are more difficult
to interpret directly. We thus omit this analysis and instead calculate the maximum
intensity and derivative after smoothing the observed data by projection onto the
first ten ROIPCs as in Section 3.1.
The results of these calculations are shown in Figure 6 for each study visit over ap-
proximately one year. All of the points are jittered slightly, and points corresponding
to voxels that are farther from the boundary are also shifted to the right for clarity
in illustration.
[Figure 6 here]
The top row of Figure 6 shows the evolution of the enhancement in this ROI
over approximately one year. On the left half of the Figure, the observed maximum
intensity after smoothing is shown. On the right side, the maximum derivative after
smoothing is shown. The bottom row of the figure shows maps of the estimated
parameter in the ROI at two time points, indicated in the longitudinal plots by an
appropriately shaded gray bar. From the longitudinal plot of the observed maximum
on the left of Figure 6, we see that there are peaks in the observed maximum both in
16
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late March and in May. In late March, we see a much lower peak of about 1 normalized
unit that is slightly more pronounced in some voxels closer to the boundary (note the
group of cyan points that are higher than the purple points at that visit). In May,
on the other hand, we see a much more dramatic peak of up to 5 normalized units
and the center of the ROI has a much higher maximum than the boundary (note the
group of purple points are higher than the other colors at that visit). The maximum
derivative (shown on the right of Figure 6) does not show any significant enhancement
in March. It does, however, show higher values in November, which are difficult to
interpret as there is no corresponding spike in the maximum observed intensity.
We model the parameters longitudinally using a Bayesian penalized thin-plate
spline. To capture spatiotemporal features, we stratify by distance from the boundary
in 4 categories. From Figure 6, we see that the variance of the functionals of interest
differs between visits. To address this, we fit:
φ(t; v, d) ∼ N [µ(t; d), τ
()
t,d ]
µ(t; d) = β0,d + β1,dt+
K∑
k=0
bk,d|t− κk|
3 (3)
where bk,d ∼ N(0, τ
(b)
d ), τ
()
t,d ∼ Γ(10
−6, 10−6), β1,d, β2,d ∼ N(0, 10
−6), and τ
(b)
d ∼
Γ(10−6, 10−6) for v ∈ V , t = κ1, . . . , κK , and d = 1, 2, . . . , D, using WinBUGS
(Crainiceanu et al., 2007). Here, φ(t; v, d) is the outcome (maximum intensity or
derivative) for voxel v in distance stratum d in the ROI observed at visit t, κ1, . . . , κv
are the visit dates taken as spline knots, N(µ, τ) is the normal distribution with
mean µ and precision τ , and Γ(a, b) is the gamma distribution with mean a/b. We
run 500000 iterations and the first 20000 are discarded as burn-in. Convergence of the
chains is verified through inspection of the chain history plots. The posterior mean
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of µ(t; d) for each distance stratum is shown by a solid line in the respective color
in Figure 6 (with cyan indicating voxels near the boundary and purple indicating
the center), and dotted lines indicate pointwise 95% credible intervals. The trends
in the observed data described above are clearly recognized by the smooth longitudi-
nal model; the smooth fits of the maximum intensity have peaks in late March and
May, and the maximum derivative shows higher values in May and November. This
methodology allows us to accurately quantify longitudinal changes in the time series
behavior. The interpretation of these results in terms of enhancement versus non-
enhancement using this model, however, is more challenging. Thus, we also consider
the EPIC-based modeling, which induces natural classification of enhancing voxels at
each visit.
4.2 Longitudinal Semiparametric Analysis
Using the EPIC model-selection approach for the ROI at each visit, we estimate
which voxels are enhancing and which are not. The proportion of voxels in which
EPIC selected model (1) at each time point is shown at the bottom of the top plot
in Figure (7), ranging from 0 to 88%. There are two time calendar periods in which
enhancement seems likely; the first is in late March and the second is from May
through July. This is in agreement with our findings from the FPCA analysis of
maximum intensity.
[Figure 7 here]
18
http://biostats.bepress.com/jhubiostat/paper231
To investigate this further, we model this voxel-level binary (enhancing vs. non-
enhancing) process. We fit:
Z(t; v, d) ∼ Bernoulli[p(t; d)]
logit[p(t; d)] = β0,d + β1,dt+
K∑
k=0
bk,d|t− κk|
3 (4)
where bk,d ∼ N(0, τ
(b)
d ), τ
(b)
d ∼ Γ(10
−6, 10−6), and β1,d, β2,d ∼ N(0, 10
−6) for v ∈ V ,
t = κ1, . . . , κK , and d = 1, 2, . . . , 4, and where Z(t; v, d) is the indicator that voxel v in
stratum d is enhancing at time t. The fitted values from this model and the credible
intervals are also shown in the top plot in Figure 7. These results further support
our hypothesis that there are two calendar time intervals during which enhancement
occurs in the ROI.
We calculate the maximum derivative and maximum fitted intensity from model
(1) at each visit to describe enhancement trajectories. To study these behaviors
longitudinally, we fit model (3) for both of these quantities in voxels that were selected
by EPIC as enhancing. The results are shown as the solid and dashed lines in the
first row of Figure 7. From these plots, we see that the enhancement in late March
is much more subtle than the one in May; the maximum intensity is much lower and
the maximum derivative is also lower. Additionally, the maps from late March show
higher intensity and rate in a region near the boundary whereas the May enhancement
is closer to the center of the ROI. To explore this further, we inspect the maps of the
parameters of interest and the observed data.
The observed image of the more prominent enhancement from May is shown in
Figure 1 in the bottom row, and is located to the top right of the ROI. On the other
hand, the images from late March are shown the middle row, and the enhancement
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is towards bottom left of the ROI. This enhancement is difficult to see directly by
inspection, but EPIC recognizes it and allows us to quantify its behavior. In fact,
this ROI contains two lesions which developed many years apart that are spatially
very close. The first, located to the upper right of the ROI is the more prominent
enhancing lesion visible in May and the second, found on the bottom left, is a subtly
enhancing older lesion which was observed on MRI years prior to our study. The latter
is of scientific interest as enhancement is traditionally thought of as a phenomenon
associated with newer lesions; subtle enhancement in older lesions indicates chronic
activity and has been reported rarely (Soon et al., 2007; Ge et al., 2005) and its
observation using DCE-MRI not been documented in the literature.
5 Summary and Future Directions
In this paper, we demonstrate comprehensive analysis techniques for studying the evo-
lution of BBB disruption in white-matter lesions in subjects with MS using DCE-MRI
data. We suggest a semiparametric methodology and a refined two-stage FPCA-based
alternative for capturing subtle features of enhancement. Using these techniques, we
quantify enhancement at each visit and we use Bayesian smoothing techniques to
model longitudinal trends. Through our analysis, we discover an older MS lesion
which shows subtle enhancement properties. It is characterized by low maximum
intensity and enhancement rate, but is clearly classified as enhancing by EPIC; this
finding was confirmed by an experienced MS neuroradiologist. This is previously un-
documented using DCE-MRI and is of scientific and clinical interest as it may indicate
a chronically active lesion.
Our semiparametric method identifies the lesion as enhancing in late March, but
it does not find the lesion to be enhancing in early March nor later in the study. This
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is surprising as the lesion was observed many years before the start of the study, and
such an old a lesion would likely have stable enhancement properties.
There are several limitations to the data, however, which could explain our obser-
vations. The first is that the early March and May visit DCE-MRI sequences were
acquired using 1.5 Tesla MRI scanner, whereas the late March sequence was acquired
using a newer and more powerful 3 Tesla scanner. However, the scans were all inter-
polated to a common spatial grid with voxels measuring 1mm x 1mm x 1mm, and
they were acquired using similar techniques. From a practical perspective, there is
no evidence that interpolation in any way contributed to the consistent and highly
localized results we are seeing. In addition, scanner strength within the study is
becoming increasingly consistent, as more subjects are scanned with the standard 3
Tesla strength. Thus, for our purposes we consider the images as directly comparable.
The second possibility, which has important implications for design, relates to
the length of the DCE-MRI sequences. The late March sequence was unusually long
(146 minutes of observation post-injection), especially compared to those taken at the
early March (13 minutes) and May (23 minutes) visits. To investigate this further we
truncated all data acquired beyond 15 minutes post-injection and we found that only
20% of voxels were deemed enhancing by EPIC, compared to the 76% found using
the full 2.5 hours of data. This indicates that our sensitivity for subtle enhancement
depends heavily on the DCE-MRI sequence duration. In the future, we hope to
consider the optimal spacing of the scans during a study visit; for example, it may be
that acquiring many scans later in the visit yields higher sensitivities for identifying
enhancement.
Although EPIC recognizes the subtle enhancement in late March, only part of
this enhancement is captured in the ROI. This is because the whole-brain FPCA
methodology that we use to identify enhancing ROIs does not recognize the subtle
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enhancement behavior; we consider these voxels in the more refined analyses only
because they overlap with the prominent enhancement in May. Thus, our techniques
would not be ideal for screening for subtle enhancement. To accomplish this goal, one
might conduct the EPIC analysis within all lesions as identified by a segmentation
algorithm such as Lesion-TOADS (Shiee et al., 2010).
Another limitation of our data involves registration. In particular, we use an
automated registration technique that, similarly to its competitors, is imperfect. This
is noticeable in Figure 1: in the early March visit, there is a darkening at the bottom
right of the field of view. This is part of the lateral ventricle and is not part of this
slice in the later visits, indicating a discrepancy in the image registration. Although
in extreme cases this could be problematic, our longitudinal methodologies are robust
to such minor errors.
In this work, we introduce EPIC for model selection at the voxel level. This is
crucial for parametric modeling as standard pharmacokinetic models are not directly
applicable for whole-brain DCE-MRI data. To address this, we choose the model
which maximizes EPIC at each voxel at each visit. This gives a natural segmentation
of ROIs into enhancing and non-enhancing voxels, and allows for the quantification
of enhancement. For this work, we chose γ = 4 as it corresponds to the likelihood
ratio test for an extra parameter in the simplest nested scenario. In other applications,
other choices of γ may be better; for example, in scenarios where only very prominent
enhancement is of interest, higher values may be more appropriate.
An important distinction between our use of EPIC and the classical use of AIC
as a model selection criterion involves sample size. In some more standard scenarios,
AIC has been shown to have desirable properties for model selection asymptotically
(Shao, 1997). This is not relevant for our problem, as the number of scanning times
for the DCE-MRI sequence is fixed. Instead, our interest is in classifying enhancement
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in a large number of voxels. By varying γ, we control error rates using EPIC.
The longitudinal modeling we suggest in this paper uses flexible Bayesian smooth-
ing techniques based on parameters estimated within study visits. One may also con-
sider generalized additive modeling of these quantities (Hastie and Tibshirani, 1990)
or quantile-based smoothing methods (Koenker and Hallock, 2001). Alternatively,
longitudinal parametric models can be used to test hypotheses about the longitudi-
nal evolution of enhancement. All of these models can include spatial information;
we used distance to a boundary, but more complex spatiotemporal modeling can also
be conducted.
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Figure 1: DCE-MRI data from the last subject in one axial slice. On the left, the
entire slice is shown. On the right, a region of interest in magnified. Each row
corresponds to data acquired during a single study visit and each column corresponds
to the within-visit time at which the image was taken. The green contour indicates
a region of interest in which enhancement occurs during at least one visit.
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Figure 2: Observed and fitted time series from three anatomical locations from the
subject shown in Figure 1. The observed time series are shown as points, and fitted
time series are shown in lines on top of the observed data. Each column corresponds
to an anatomical location where the observed time series are found, and each row
corresponds to the location associated with the model fitted. The plots falling on the
diagonal indicate appropriate fits.
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Figure 3: Population-level functional principal components from the whole-brain anal-
ysis and score maps. These first four PCs explain over 99.5% of the variation. In the
top row, the PCs are shown with the contribution to percentage variance explained
from each component. The bottom row shows score maps for the axial slice shown in
Figure 1 as observed during the visit in May.
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Figure 4: Functional principal components from the within-ROI analysis. The first
three PCs, which explain 99% of the variation, are shown in the bottom row. The
percentage of variance explained by each component is also listed in the respective
plotting areas. Above these are the score maps for the ROI shown in Figure 1 as
observed during the visit in May, with area outside of the ROI masked as black.
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Figure 5: Comparison between two-stage FPCA-based and EPIC-based estimates of
maximum derivative and maximum intensity in each voxel. These are shown for the
ROI from Figure 1 as observed during the visit in May. In part a of the figure, spatial
maps are shown. In part b, we show the time series corresponding to a few voxels
from these regions in shades of gray. Below these we show the smoothed time series
in the middle row, and the fitted values from model (1) in the bottom row.
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Figure 6: Longitudinal evolution of the time series maximum and maximal derivative
in voxels from the enhancing ROI shown in Figure 1 after smoothing. In the top
row, each point corresponds to a single voxel at a study visit, and distance to the
boundary is shown in color. In the bottom row, we provide maps of the estimated
parameter in the ROI at two time points, indicated in the longitudinal plots by an
appropriately shaded gray bar.
32
http://biostats.bepress.com/jhubiostat/paper231
04
Mar May Jul Sep Nov Jan
0
.0
0
.5
1
.0
Date
P
ro
b
a
b
ili
ty
 o
f 
E
n
h
a
n
c
e
m
e
n
t
0.02 0.76 0.1 0.88 0.96 0.74 0.06 0.01 0
1.0
1.7
2.3
3.0
3.6
4.3
Distance to Boundary
Mar May Jul Sep Nov Jan
 
!
0
2
4
6
Date
O
b
s
e
rv
e
d
 M
a
x
im
u
m
Mar May Jul Sep Nov Jan
0
1
2
3
4
Date
M
a
x
im
u
m
 D
e
ri
v
a
ti
v
e
0
4
Late March May Late March May
0
3.5
0
3.5
Figure 7: Longitudinal evolution of the proportion of voxels deemed enhancing by
EPIC (top row), and the model-based maximum and maximal derivative (middle)
in voxels from the enhancing ROI shown in Figure 1. Each point corresponds to a
single voxel at a study visit, and distance to the boundary is shown in color. The
proportion of voxels deemed enhancing at each time point is provided in black text
in the top plot for comparison. In the bottom row, we provide maps of the estimated
parameter in the ROI at two time points, indicated in the longitudinal plots by an
appropriately shaded gray bar.
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Disease-Modifying Disease Number of Number of
ID Sex EDSS Treatment Age Duration Study Visits ROIs
1 male 5.5 treated 46 21 3 1
2 male 2.5 treated 52 17 7 9
3 male 1.5 treated 43 14 5 1
4 female 1.5 treated 41 10 5 1
5 female 1.0 treated 32 9 6 4
6 female 1.0 treated 46 6 4 2
7 female 1.0 treated 33 5 5 1
8 male 1.5 treated 58 5 5 2
9 male 1.0 treated 39 7 5 3
10 female 1.0 treated 25 1 7 3
11 female 1.0 treated 28 0.5 9 4
12 male 0.0 untreated 30 3 8 5
13 female 1.5 treated 47 8 4 1
14 female 2.5 untreated 40 7 10 8
15 female 2.5 untreated 40 4 9 11
Table 1: The numbers of study visits and subject-level enhancing ROIs larger than
30mm3 for 15 subjects with MS listed with descriptive statistics at baseline including
sex, age, expanded disability status scale (EDSS, Kurtzke (1983) with 0 indicating no
disability and 7 indicating restriction to a wheelchair), treatment information, and
disease duration (in years).
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